Work Here?
Overview
Deep 6 AI provides a software platform that speeds up clinical-trial patient recruitment. It uses AI to scan electronic medical records and identify patients who meet complex trial criteria, doing so in minutes rather than months. The platform is delivered as a SaaS product, with subscription pricing that can vary by service level and organization size. This makes it faster and cheaper for pharmaceutical companies, research organizations, and healthcare providers to find eligible participants, enabling more trials and lowering drug development costs. Compared with typical approaches, Deep 6 AI differentiates itself by the speed and scale of patient matching across medical records to support rapid enrollment. The company’s overarching goal is to shorten recruitment timelines, reduce trial costs, and help bring new therapies to patients faster.
About Deep 6 AI
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$17.5M
Headquarters
Pasadena, California
Founded
2015
Simplify's Take
What believers are saying
- Tempus AI acquisition expands Deep 6 AI's reach into Tempus' 7 million patient multimodal dataset.
- AWS-built platform enables real-time adaptive trials and synthetic control arms.
- OSUCCC implementation in January 2023 boosts enrollment of underserved populations.
What critics are saying
- Tempus AI acquisition ends Deep 6 AI independence, obsoleting standalone platform.
- FDA AI/ML SaMD guidelines ban EMR mining, halting client onboarding within 12 months.
- Hugging Face Transformers replace Spark NLP, slashing extraction edge in 12 months.
What makes Deep 6 AI unique
- Deep 6 AI mines structured and unstructured EMR data using AI and NLP for precise patient-trial matching.
- Platform integrates with 750+ sites covering 30 million patients across NCI centers.
- Graticule partnership develops first-of-its-kind algorithm sifting EMR from 1,000+ facilities.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$17.4M
Below
Industry Average
Funded Over
3 Rounds
Industry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Vacation
Paid Sick Leave
401(k) Retirement Plan
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 21%1 year growth
↑ 21%2 year growth
↑ 122%Tempus AI has acquired Deep 6 AI to expand its reach and enhance offerings in precision medicine.
DELRAY BEACH, Fla., Dec. 17, 2024 /PRNewswire/ -- The global artificial intelligence in clinical trials market is forecasted to grow steadily from US$1.20 billion in 2023 to US$1.35 billion in 2024, ultimately reaching an impressive US$2.74 billion by 2030, driven by a robust CAGR of 12.4%. Some of the key elements fueling the expansion of the AI in clinical trials market, are the high rate of clinical trial failures, the increasing need of anticipating drug pharmacokinetics, pharmacodynamics, and management of toxicity. According to a research article published by the National Library of Medicine in February 2022, the drug discovery and development process takes about 10-15 years for a new drug to be approved for clinical use. And 90% of the drug candidates fail during the phases I, II, and III of clinical trials and drug approvals. The reasons that may result in failure include but not limited to effectiveness in a clinical setting, high levels of toxicity that cannot be managed, suboptimal drug-like characteristics, a lack of real commercial drivers, and poor strategic design
PASADENA, Calif., Aug. 1, 2023 /PRNewswire/ -- Texas Tech University Health Sciences Center (TTUHSC) and Deep 6 AI announced a collaboration, joining forces to integrate artificial intelligence (AI) within TTUHSC's electronic medical record (EMR) system to improve patient access to clinical trials.Texas Tech University Health Sciences Center Partners with Deep 6 AI to Launch an AI Program for Clinical TrialsTTUHSC will use Deep 6 AI to precision-match patients to their clinical trials in real time. This process will allow researchers to find the right patients for their trials in minutes, which will greatly reduce the workload on their staff. By using these AI tools, TTUHSC researchers will ultimately give more patients access to participate in clinical trials and will be able to use any resulting therapies to treat patients even faster. This partnership further expands the Deep 6 AI ecosystem, which consists of millions of unique patient records and thousands of trial sites accessible to sponsors for their research."Clinical trials are extremely valuable because they provide patients with opportunities to access therapies they otherwise would not have access to," John Griswold, M.D., executive director of the TTUHSC Clinical Research Institute said. "This collaboration with Deep 6 AI will enhance our ability to bring cutting-edge treatments to our community."One of the most time-consuming components of clinical research is finding patients who match the specific criteria needed for the study
Join this webinar for a live demonstration of a precision-matching software that streamlines the entire clinical trial process by using AI to search both structured and unstructured data such as patient medical records in real time. .
When asked to comment, Deep6.AI reached out to the website planet via email and informed us that they were working on launching a new AI-powered chatbot named “Deep 6.”
There are no jobs for Deep 6 AI right now.
Find jobs on Simplify and start your career today
About Deep 6 AI
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$17.5M
Headquarters
Pasadena, California
Founded
2015
There are no jobs for Deep 6 AI right now.
Find jobs on Simplify and start your career today